Peptide Antibiotics Market Size, Share & Trends Analysis Report By Product Type, By Disease, By Route Of Administration (Oral, Injectable, Topical), By Distribution Channel, By Region- Global Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2022-2030

According to Nova one advisor, the global Peptide Antibiotics market size was estimated at USD 5.7 billion in 2022 and is projected to hit around USD 7.8 billion by 2030, growing at a CAGR of 4.60% during the forecast period 2022 to 2030.

Key Takeaways:

• By Disease, the U.S. Peptide Antibiotics market was valued at USD 1.9 Billion in 2021 and expected to witness growth at a CAGR of 4.8% from 2022 to 2030.
• In 2021, the non-ribosomal synthesized peptide segment dominated the market owing to their higher demand
• The retail pharmacy segment held the highest share and is likely to maintain its dominance throughout the forecast period
• Asia Pacific region is expected to witness the highest CAGR over the forecast period owing to factors such as, rising prevalence of infectious diseases, and availability of large patient pool
• North America dominated the overall market in 2021 due to the higher demand for peptide antibiotics products, presence of leading market players, and increased research activities within the region

The market is expected to witness growth opportunities owing to factors such as the increasing research and development activities in field of peptide antibiotics coupled with high number of drug approvals. Moreover, surge in cases of antimicrobial resistance cases and possibility of side effects from the conventional antibiotics are also expected to drive the market during the forecast period.

Increasing prevalence of cancer and other infectious diseases are expected to propel the growth over the forecast period. For instance, according to the CDC, United States reported 1,752,735 new cancer cases along with 599,589 deaths in 2019. For every 100,000 people, 439 new cases were found and 146 people died due to cancer. Further, according to Globocan 2020, U.K. had 457,960 new cases with 179,648 deaths in 2020. The most common types of malignancies were breast, prostate cancer and Non-Hodgkin’s lymphoma.

There are some of the peptide antibiotics which are used to treat cancers such as, NHL, Hodgkin’s lymphoma, and certain types of skin malignancies. According to Globocan 2020, there were 5,44,352 Non-Hodgkin lymphoma cases and 83,087 Hodgkin’s lymphoma cases. The efficiency of various existing products is expected to result into higher revenues owing to doctor recommendations . For instance, BLEOMYCIN for injection USP is the mixture of cytotoxic glycopeptide antibiotics that is isolated from Streptomyces verticillus and is used for the treatment of testicular carcinoma, squamous cell carcinoma, and various types of lymphomas.

Moreover, ongoing product approvals and strategic initiatives undertaken by market players such as partnerships, collaborations, product launches, and expansions are expected to fuel market growth during forecast period. For instance, in July 2021, AbbVie Inc announced that the U.S. FDA approved DALVANCE for the treatment of acute bacterial skin and skin structure infections in pediatric patients from birth. Moreover, in July 2020, Sandoz International GmbH announced introduction of Daptomycin injection 500 mg, a generic version of Cubicin, in the U.S. market for the treatment of adult patients with complicated skin and skin structure infections and several type of bloodstream infections.

Report Scope of the Peptide Antibiotics Market

Product Type Insights

The non-ribosomal synthesized peptide antibiotics segment held the largest revenue share of 73.2% in 2021 and is likely to maintain its dominance over the forecast period. The growth of the non-ribosomal synthesized peptide antibiotics is attributed by increasing demand for non-ribosomal synthesized antibiotics and rising availability of non-ribosomal synthesized antibiotics.

There are several non-ribosomal synthesized antibiotics available in market for peptide antibiotics. For instance, BLEOMYCIN (Glyco peptide product) manufactured by Pfizer Inc., is a non-ribosomal synthesized peptide antibiotic isolated from a strain of Streptomyces verticillus. BLEOMYCIN is used in the treatment of squamous cell carcinoma, testicular carcinoma, and lymphoma. Moreover, Bacitracin vial manufactured by Xellia Pharmaceuticals is indicated for the treatment of infants with pneumonia and empyema.

Disease Insights

The skin infection segment held the largest revenue share of 31.3% in 2021 and is likely to dominate the market during the forecast period. The growth of the skin infection segment is augmented by rising prevalence of skin infections such as, cellulitis, impetigo, furuncles, carcuncles, and others, and wide availability of products for treatment of bacterial skin infections. For instance, CUBICIN RF (daptomycin for injection) a type of lipo peptide product manufactured by Merck & Co., Inc. is used for the treatment of pediatric patients and adults with complicated skin and skin structure infections caused by S. aureus, S.pyrogenes, S. agalactiae.

However, the blood stream infection segment is anticipated to register fastest growth rate during the forecast period. The growth of the segment is augmented by rising incidences of blood stream infections, rising awareness about blood stream infections, and availability of robust product portfolio for management of blood stream infections. For instance, Polymyxin B vials manufactured by Xellia PHARMACEUTICALS is used for the treatment of blood-stream infections due to strains such as, E-Coli, Pseudomonas aeruginosa, H. influenza.

Distribution Channel Insights

The hospital pharmacies segment held the highest revenue share of 46.4% in 2021, whereas the retail pharmacies segment is expected to register fastest growth rate during the forecast period. Rising prescriptions of peptide antibiotics owing to various kind of bacterial skin infections, ophthalmic infections is a major factor expected to drive the retail pharmacy segment growth. However, the growth of hospital pharmacy segment is augmented by rising prevalence of blood stream infection, hospital acquired infection, and prolonged hospital stays.

Route Of Administration Insights

The injectable route of administration segment held the largest revenue share of 42.7% in 2021 and is expected to maintain its dominance during the forecast period. The growth of the injectable segment is attributed to factors such as availability of large number of peptide antibiotics in injectable form, efficiency, and better bioavailability from injectable peptide antibiotics.

There are a large number of products available in injectable form. For instance, DALVANCE manufactured by AbbVie Inc is administered by intravenous route as an infusion. DALVANCE is used for the treatment of various kind of skin infections. Moreover, vancomycin hydrochloride manufactured by Pfizer, Inc is given by IV infusion for the treatment of severe infections caused by susceptible strains of methicillin-resistant staphylococci.

Regional Insights

North America dominated the market for peptide antibiotics and accounted for revenue share of 41.9% in 2021 followed by Europe. Factors such as presence of large number of market players and strategic initiatives taken by key players are some of the major factors responsible for the growth.

Moreover, rising demand for antibiotics in this region, and increase in R&D activities in the region are also expected to drive the industry during the forecast period. Asia Pacific is expected to be the fastest growing region over the forecast period owing to factors such as increase in prevalence of various infectious diseases, rising geriatric population, and surge in awareness amongst patients about their health.

Some of the prominent players in the Peptide Antibiotics Market include:

• Pfizer Inc.
• Merck & Co., Inc.
• AbbVie Inc
• GSK Group of Companies
• Sandoz International GmbH
• Xellia Pharmaceuticals
• AuroMedics Pharma LLC
• Theravance Biopharma 

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Peptide Antibiotics market

• Product Type

• Ribosomal Synthesized Peptide Antibiotics
• Non-Ribosomal Synthesized Peptide Antibiotics
• Disease
• Skin Infection
• HABP/VABP
• Blood Stream Infection
• Others
• Route of Administration
• Oral
• Injectable
• Topical
• Others
• Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Geography

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East & Africa (MEA)

Key Benefits for Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the global Peptide Antibiotics industry analysis from 2022 to 2030 to identify the prevailing Peptide Antibiotics industry opportunity.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the global Peptide Antibiotics industry segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global Peptide Antibiotics industry trends, key players, market segments, application areas, and market growth strategies.